How many Baricitinib clinical trials are there?

156 Baricitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 28 are actively recruiting participants. 65 are marked completed.

Are Baricitinib clinical trials recruiting in 2026?

Yes — 28 Baricitinib trials are actively recruiting in 2026, with 73 U.S. sites across 29 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Baricitinib being studied for?

Baricitinib is being studied for Rheumatoid Arthritis, Atopic Dermatitis, COVID-19, Healthy Volunteers, Alopecia Areata and 149 more. The trials are grouped by indication on this page.

What phase is Baricitinib in?

Baricitinib clinical trials span 12 Phase 4, 46 Phase 3, 48 Phase 2, 17 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Baricitinib clinical trials?

The lead sponsor across the most Baricitinib trials is Eli Lilly and Company, with 81 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Baricitinib Clinical Trials (2026): 156 Studies for Rheumatoid Arthritis & Atopic Dermatitis

Creator: Hipa.ai Research
Published: 2026-05-20T23:40:15.026Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

156 Baricitinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 88 indications (including Rheumatoid Arthritis & Atopic Dermatitis) and 147,315 total planned enrollment. 46 Phase 3 Baricitinib trials and 48 Phase 2, 12 Phase 4 are listed. 43 Baricitinib clinical trials are actively recruiting at 73 U.S. sites across 29 states. Most recent activity: NCT04381936 (Sep 2038).

Where to Participate: All Baricitinib Trial Sites in the U.S. (73 sites across 29 states)

Every actively recruiting Baricitinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Total Skin and Beauty Dermatology Center, PC	Birmingham35205	NCT05723198	Map
AZ	Investigate MD	Scottsdale85255	NCT05723198	Map
AZ	University of Arizona	Tucson85724	NCT06631287	Map
CA	Medvin Research - Covina	Covina91722	NCT05003310	Map
CA	Dermatology Research Associates	Los Angeles90045	NCT05723198	Map
CA	University of California, Los Angeles (UCLA)	Los Angeles90024	NCT06631287	Map
CA	University of California, San Diego/Rady Children's Hospital, San Diego - Pediatric & Adolescent Dermatology	San Diego92123	NCT05723198	Map
CA	The Permanente Medical Group, Inc.	San Francisco94118	NCT05723198	Map
CA	University of California San Francisco	San Francisco94143	NCT06631287	Map
CA	Southern California Dermatology, Inc.	Santa Ana92701	NCT05723198	Map
CA	Medvin Research - Whittier	Whittier90602	NCT05003310	Map
CO	University of Colorado I Anschutz Medical Campus	Aurora80045	NCT06631287	Map
CT	Yale University	New Haven06510	NCT06631287	Map
FL	University of Florida College of Medicine	Gainesville32610	NCT06631287	Map
FL	Solutions Through Advanced Research, Inc.	Jacksonville32256	NCT05723198	Map
FL	University of Florida	Jacksonville32209	NCT02735707	Map
FL	Pediatric Skin Research, LLC	Miami33156	NCT05723198	Map
GA	Emory University	Atlanta30322	NCT06631287	Map
GA	Emory University	Atlanta30322	NCT07003997	Map
GA	Emory University Hospital	Atlanta30322	NCT05452564	Map
GA	Emory University Hospital	Atlanta30322	NCT05849038	Map
GA	Grady Memorial Hospital	Atlanta30303	NCT05452564	Map
GA	Grady Memorial Hospital	Atlanta30303	NCT05849038	Map
GA	Skin Care Physicians of Georgia	Macon31217	NCT05723198	Map
IL	Illinois Research Network (ILLInet), University of Illinois Chicago	Chicago60608	NCT06631287	Map
IL	University of Illinois Health	Chicago60612	NCT02735707	Map
IL	Northshore University Healthsystem	Skokie60077	NCT05723198	Map
IN	Dawes Fretzin Clinical Research Group, LLC	Indianapolis46250	NCT05723198	Map
IN	The South Bend Clinic Center for Research	South Bend46617	NCT05723198	Map
IA	Iowa Diabetes and Endocrinology Research Center	West Des Moines50266	NCT07222137	Map
MD	National Institutes of Health Clinical Center	Bethesda20892	NCT06923072	Map
MD	National Institutes of Health Clinical Center	Bethesda20892	NCT07262983	Map
MD	The Osteoporosis & Clinical Trials Center	Hagerstown21740	NCT05003310	Map
MD	DermAssociates PC.	Rockville20850	NCT05723198	Map
MA	Brigham and Women's Hospital	Boston02115	NCT06631287	Map
MI	University of Michigan	Ann Arbor48109	NCT02735707	Map
MI	Michigan Center for Research Company	Clarkston48346	NCT05723198	Map
MN	University of Minnesota	Minneapolis55455	NCT06631287	Map
MN	University of Minnesota Medical School	Minneapolis55455	NCT05723198	Map
MO	MediSearch Clinical Trials	Saint Joseph64506	NCT05723198	Map
NE	Advanced Skin Research Center	Omaha68144	NCT05723198	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT03414502	Map
NY	NYU Langone	Brooklyn11201	NCT05003310	Map
NY	NYU Langone Health - Brooklyn	Brooklyn11220	NCT06631287	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT02735707	Map
NY	Montefiore Medical Center	The Bronx10467	NCT05723198	Map
NC	Dermatology Specialists of Charlotte	Charlotte28277	NCT05723198	Map
NC	OnSite Clinical Solutions	Charlotte28277	NCT05723198	Map
OH	Bexley Dermatology Research	Bexley43209	NCT05723198	Map
OH	The MetroHealth System	Cleveland44109	NCT06631287	Map
OH	University Hospitals Cleveland Case Western	Cleveland44106	NCT06631287	Map
OH	The Ohio State University Wexner Medical Center	Columbus43210	NCT02735707	Map
OK	Vital Prospects Clinical Research Institute, P.C.	Tulsa74136	NCT05723198	Map
OR	Northwest Dermatology Institute	Portland97210	NCT05723198	Map
OR	Oregon Health & Science University	Portland97239	NCT05003310	Map
OR	Oregon Health and Science University	Portland97239-3098	NCT02735707	Map
PA	Altoona Center for Clinical Research	Altoona16635	NCT05003310	Map
PA	University of Pittsburgh Medical Centre	Pittsburgh	NCT02735707	Map
SC	Medical University of South Carolina	Charleston29425	NCT05723198	Map
TN	International Clinical Research - Tennessee (IC Research)	Murfreesboro37130	NCT05723198	Map
TN	Vanderbilt University Medical	Nashville37203	NCT06631287	Map
TX	Arthritis & Rheumatology Institute	Allen75013	NCT05003310	Map
TX	St. David's Healthcare	Austin78705	NCT05003310	Map
TX	Tekton Research	Austin78745	NCT05003310	Map
TX	Pediatric Dermatology of North Texas	Grapevine76051	NCT05723198	Map
TX	Southwest Rheumatology Research	Mesquite75150	NCT05003310	Map
TX	Texas Dermatology and Laser Specialists	San Antonio78218	NCT05723198	Map
TX	University of Texas at San Antonio	San Antonio78229	NCT06631287	Map
TX	Complete Dermatology	Sugar Land77479	NCT05723198	Map
VA	Virginia Clinical Research	Norfolk23502	NCT05723198	Map
WA	Swedish Medical Center	Seattle98104	NCT06631287	Map
WV	West Virginia Clinical and Translational Science Institute	Morgantown26506-7015	NCT06631287	Map
WI	University of Wisconsin-Madison	Madison53715	NCT05723198	Map

Baricitinib clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	terminated	withdrawn	not yet recruiting	unknown	approved for marketing	Total
Early P1			1						1
P1	2	1	14						17
P1/P2	2		3			1			6
P2	7	1	17	4	1	8	10		48
P2/P3	1	1	2	2	1	1	3		11
P3	12	3	19	4	2	2	4		46
P4	1	2	4	1		2	2		12
N/A	3		5			1	5	1	15

Recruiting Baricitinib clinical trials (43)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT04381936	RECOVERYRandomised Evaluation of COVID-19 Therapy	P3	Pneumonia	70,000	Mar 2020
NCT05723198	BRAVE-AA-PEDSA Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata	P3	Areata Alopecia	595	Feb 2023
NCT05003310	ConsideRAte Study - Splenic Stimulation for RA	N/A	Rheumatoid Arthritis	28	Oct 2021
NCT07543458	DEN-HOSTTherapeutics for Moderate and Severe Dengue	P3	Dengue	8,800	Oct 2026
NCT07222137	BARICADE-DELAYA Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults	P3	Diabetes Mellitus, Type 1	150	Jan 2026
NCT03773965	JUVE-XA Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis	P3	Juvenile Idiopathic Arthritis	190	Apr 2019
NCT07448363	Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica	—	Atopic Dermatitis	50	May 2026
NCT06381661	PALETTEAdaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial	P2	Sepsis	2,000	May 2026
NCT06923072	Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement	P2	Kohlmeier-Degos Disease	12	Feb 2026
NCT07081763	Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption	P2	HIV-1-infection	191	May 2026
NCT07262983	Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis	P1	Hyper IgE Syndrome From STAT3 Mutation	20	Jun 2026
NCT07268534	BOOSTERSBiologics in Folliculitis Decalvans : an Adaptative Trial Research	P2	Folliculitis Decalvans (FD)	120	Apr 2026
NCT07003997	JAK Signaling in Depression	P2	Major Depressive Disorder	100	Sep 2025
NCT05651880	JAKUVEITEEfficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis	P3	Active Non-anterior Non-infectious Uveitis	33	Jul 2026
NCT03358693	MSIDMolecular Signatures in Inflammatory Skin Disease	—	Atopic Dermatitis	300	Jan 2017
NCT07535645	BAPTBaricitinib for Post-HSCT Persistent Thrombocytopenia	P1/P2	Persistent Thrombocytopenia	28	Apr 2026
NCT07279688	JADORE-BARIJustification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica	P3	Polymyalgia Rheumatica (PMR)	140	Dec 2025
NCT06687551	JAK-TAPJAK Inhibitor Dose TAPering Strategy Study	P4	Rhumatoid Arthisis	308	Jan 2025
NCT03414502	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response	P3	Rheumatoid Arthritis	400	Dec 2007
NCT07554222	Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration	P1	Healthy	160	Apr 2026
NCT06868381	A Trial of Baricitinib in Patients With Cardiac Sarcoidosis	P2	Cardiac Sarcoidosis	10	Apr 2026
NCT06490757	JAKIHA Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas	P2	Inflammatory Hepatocellular Adenoma	25	Oct 2024
NCT07222332	LY3009104A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)	P3	Diabetes Mellitus, Type 1	300	Feb 2026
NCT06849908	Baricitinib in the Treatment of Intestinal Behçet's Syndrome	P2	Behcet Syndrome, Intestinal Type	56	Nov 2024
NCT02735707	REMAP-CAPRandomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia	P3	Community-acquired Pneumonia, Influenza, COVID-19	20,000	Apr 2016
NCT04972760	BIRDBaricitinib in Patients With Relapsing or naïve Dermatomyositis	P3	Dermatomyositis	62	Aug 2022
NCT07209267	Baricitinib Curative Repression of HIV-1	P2	HIV Infection	20	Jul 2026
NCT07449910	Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial	P2/P3	Acute Ichemic Stroke	750	Mar 2026
NCT05452564	Baricitinib for Reduction of HIV - CNS	P2	Human Immunodeficiency Virus	95	May 2023
NCT05849038	Inflammation and Depression in People With HIV	P2	HIV	60	Dec 2023
NCT06631287	REVERSE-LCRandomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID	P3	Long COVID	550	Oct 2024
NCT06439615	BLISSBaricitinib for the Lung Injury Following Spontaneous SAH	P2	Spontaneous Subarachnoid Hemorrhage	100	Aug 2024
NCT06768294	BAPTISTBaricitinib in CPPD - the BAPTIST Study	P2	Calcium Pyrophosphate Deposition Disease	32	Jan 2025
NCT07357649	BAR-RABaricitinib Effects on Procoagulant State in Rheumatoid Arthritis	P4	Rheumatoid Arthritis	100	Jan 2026
NCT06797310	MQ7422Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study	P2	Alopecia Areata	30	Jan 2025
NCT06573593	Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study	—	Alopecia Areata	150	Jul 2024
NCT06065046	Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions	P2	Traumatic Brain Injury	100	Nov 2023
NCT04088396	LY3009104A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)	P3	Systemic Juvenile Idiopathic Arthritis	58	Feb 2020
NCT06548802	BRIGHTEfficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury	P1/P2	Pulmonary Injury After Intracerebral Hemorrhage	100	Feb 2024
NCT05955066	Effect of JAK Inhibitor on Erosion Healing in RA	P4	Rheumatoid Arthritis	60	Dec 2023
NCT05792462	Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders	P1/P2	NMO Spectrum Disorder	12	Apr 2023
NCT06768840	Vitiligo, New Treatment and Serum s100B	P2/P3	Vitiligo, Generalized	50	Oct 2024
NCT06936215	BardSScSafety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate	P3	Diffuse Cutaneous Systemic Sclerosis	24	Jan 2024

Baricitinib clinical trials by indication

Rheumatoid Arthritis (21)

NCT	Acronym	Phase	Status	Title
NCT05003310	—	N/A	recruiting	ConsideRAte Study - Splenic Stimulation for RA
NCT03414502	—	P3	recruiting	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
NCT04870203	CRI-RA	P3	active not recruiting	Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis
NCT07357649	BAR-RA	P4	not yet recruiting	Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis
NCT05955066	—	P4	recruiting	Effect of JAK Inhibitor on Erosion Healing in RA
NCT03755466	—	P2	unknown	Examination of Efficacy and Safety of Baricitinib in RA Patients
NCT03915964	RA-BRIDGE	P4	completed	A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
NCT04086745	RA-BRANCH	P4	completed	A Study of Baricitinib in Participants With Rheumatoid Arthritis
+ 13 more, see All trials below.

Atopic Dermatitis (12)

NCT	Acronym	Phase	Status	Title
NCT07448363	—	N/A	not yet recruiting	Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica
NCT03358693	MSID	N/A	recruiting	Molecular Signatures in Inflammatory Skin Disease
NCT03952559	BREEZE-AD-PEDS	P3	active not recruiting	A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
NCT05969730	—	N/A	completed	Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis
NCT03334435	BREEZE-AD3	P3	completed	A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis
NCT03428100	BREEZE-AD4	P3	completed	A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable
NCT03559270	BREEZE-AD6	P3	terminated	A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis
NCT03435081	BREEZE-AD5	P3	completed	A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis
+ 4 more, see All trials below.

COVID-19 (10)

NCT	Acronym	Phase	Status	Title
NCT04321993	COVID-19	P2	unknown	Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients
NCT05638932	—	N/A	completed	Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments
NCT04891133	Bari-SolidAct	P2/P3	terminated	EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial
NCT05082714	—	N/A	completed	Tocilizumab Versus Baricitinib in Patients With Severe COVID-19
NCT04340232	—	P2/P3	withdrawn	Safety and Efficacy of Baricitinib for COVID-19
NCT05302947	—	N/A	completed	COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU
NCT04640168	ACTT-4	P3	completed	Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
NCT04421027	COV-BARRIER	P3	completed	A Study of Baricitinib (LY3009104) in Participants With COVID-19
+ 2 more, see All trials below.

Healthy Volunteers (9)

NCT	Acronym	Phase	Status	Title
NCT02340104	LY3009104	P1	completed	A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants
NCT01960140	—	P1	completed	A Study of Baricitinib and Simvastatin in Healthy Participants
NCT01968057	—	P1	completed	A Study of Baricitinib and Ciclosporin in Healthy Participants
NCT01925144	—	P1	completed	A Study of Baricitinib and Omeprazole in Healthy Participants
NCT01937026	—	P1	completed	A Study of Baricitinib and Probenecid in Healthy Participants
NCT01924299	—	P1	completed	A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants
NCT01910311	—	P1	completed	A Study of Baricitinib and Rifampicin in Healthy Participants
NCT01896726	—	P1	completed	A Study of Baricitinib and Birth Control Pills in Healthy Females
+ 1 more, see All trials below.

Alopecia Areata (5)

NCT	Acronym	Phase	Status	Title
NCT06797310	MQ7422	P2	not yet recruiting	Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study
NCT06573593	—	N/A	recruiting	Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
NCT03570749	BRAVE-AA1	P2/P3	completed	A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
NCT03899259	BRAVE-AA2	P3	completed	A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
NCT06545110	—	P1	active not recruiting	Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib

Covid19 (4)

NCT	Acronym	Phase	Status	Title
NCT05074420	COV-BARRIER	P3	terminated	A Study of Baricitinib (LY3009104) in Children With COVID-19
NCT04832880	AMMURAVID	P3	unknown	Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)
NCT05056558	—	P3	unknown	Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19
NCT04693026	—	P3	unknown	Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients

Systemic Lupus Erythematosus (4)

NCT	Acronym	Phase	Status	Title
NCT03843125	SLE-BRAVE-X	P3	terminated	A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
NCT03616912	SLE-BRAVE I	P3	terminated	A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus
NCT03616964	BRAVE II	P3	completed	A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)
NCT02708095	LY3009104	P2	completed	A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

Healthy (3)

NCT	Acronym	Phase	Status	Title
NCT07554222	—	P1	recruiting	Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
NCT03212638	—	P1	completed	A Study of Baricitinib in Healthy Participants
NCT02758613	LY3009104	P1	completed	A Study of Baricitinib (LY3009104) in Healthy Chinese Participants

Diabetes Mellitus, Type 1 (2)

NCT	Acronym	Phase	Status	Title
NCT07222137	BARICADE-DELAY	P3	recruiting	A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222332	LY3009104	P3	recruiting	A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

Vitiligo, Generalized (2)

NCT	Acronym	Phase	Status	Title
NCT06768840	—	P2/P3	recruiting	Vitiligo, New Treatment and Serum s100B
NCT05950542	—	N/A	unknown	Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo

Diabetic Kidney Disease (2)

NCT	Acronym	Phase	Status	Title
NCT05897372	WP3	P2	terminated	Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study
NCT01683409	—	P2	completed	A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

Immune Thrombocytopenia (2)

NCT	Acronym	Phase	Status	Title
NCT05932524	—	P2	unknown	Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia
NCT05852847	—	P2	unknown	Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

Dermatomyositis (2)

NCT	Acronym	Phase	Status	Title
NCT04972760	BIRD	P3	recruiting	Baricitinib in Patients With Relapsing or naïve Dermatomyositis
NCT05361109	—	P2	withdrawn	Baricitinib for Cutaneous Dermatomyositis

Sjogren's Syndrome (2)

NCT	Acronym	Phase	Status	Title
NCT05016297	—	P2	completed	Efficacy and Safety of Baricitinib in Sjogren's Syndrome
NCT04916756	—	P1/P2	completed	A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients

COVID-19 Pneumonia (2)

NCT	Acronym	Phase	Status	Title
NCT04970719	—	P3	withdrawn	Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus
NCT04346147	Covid19COVINIB	P2	unknown	Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19

Juvenile Idiopathic Arthritis (2)

NCT	Acronym	Phase	Status	Title
NCT03773965	JUVE-X	P3	recruiting	A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03773978	JUVE-BASIS	P3	completed	A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Dengue (1)

NCT	Acronym	Phase	Status	Title
NCT07543458	DEN-HOST	P3	not yet recruiting	Therapeutics for Moderate and Severe Dengue

HIV Infection (1)

NCT	Acronym	Phase	Status	Title
NCT07209267	—	P2	not yet recruiting	Baricitinib Curative Repression of HIV-1

HIV-1-infection (1)

NCT	Acronym	Phase	Status	Title
NCT07081763	—	P2	not yet recruiting	Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption

Hyper IgE Syndrome From STAT3 Mutation (1)

NCT	Acronym	Phase	Status	Title
NCT07262983	—	P1	recruiting	Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

Sepsis (1)

NCT	Acronym	Phase	Status	Title
NCT06381661	PALETTE	P2	not yet recruiting	Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

Persistent Thrombocytopenia (1)

NCT	Acronym	Phase	Status	Title
NCT07535645	BAPT	P1/P2	not yet recruiting	Baricitinib for Post-HSCT Persistent Thrombocytopenia

Cardiac Sarcoidosis (1)

NCT	Acronym	Phase	Status	Title
NCT06868381	—	P2	not yet recruiting	A Trial of Baricitinib in Patients With Cardiac Sarcoidosis

Folliculitis Decalvans (FD) (1)

NCT	Acronym	Phase	Status	Title
NCT07268534	BOOSTERS	P2	not yet recruiting	Biologics in Folliculitis Decalvans : an Adaptative Trial Research

Active Non-anterior Non-infectious Uveitis (1)

NCT	Acronym	Phase	Status	Title
NCT05651880	JAKUVEITE	P3	not yet recruiting	Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis

Acute Ichemic Stroke (1)

NCT	Acronym	Phase	Status	Title
NCT07449910	—	P2/P3	not yet recruiting	Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial

Kohlmeier-Degos Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06923072	—	P2	recruiting	Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement

Polymyalgia Rheumatica (PMR) (1)

NCT	Acronym	Phase	Status	Title
NCT07279688	JADORE-BARI	P3	recruiting	Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica

Major Depressive Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT07003997	—	P2	recruiting	JAK Signaling in Depression

Calcium Pyrophosphate Deposition Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06768294	BAPTIST	P2	not yet recruiting	Baricitinib in CPPD - the BAPTIST Study

Rhumatoid Arthisis (1)

NCT	Acronym	Phase	Status	Title
NCT06687551	JAK-TAP	P4	not yet recruiting	JAK Inhibitor Dose TAPering Strategy Study

Behcet Syndrome, Intestinal Type (1)

NCT	Acronym	Phase	Status	Title
NCT06849908	—	P2	recruiting	Baricitinib in the Treatment of Intestinal Behçet's Syndrome

Post-Acute COVID-19 Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT05858515	REVERSE-LC	P3	withdrawn	REVERSE-Long COVID-19 With Baricitinib Study

Long COVID (1)

NCT	Acronym	Phase	Status	Title
NCT06631287	REVERSE-LC	P3	recruiting	Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Inflammatory Hepatocellular Adenoma (1)

NCT	Acronym	Phase	Status	Title
NCT06490757	JAKIH	P2	recruiting	A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas

Spontaneous Subarachnoid Hemorrhage (1)

NCT	Acronym	Phase	Status	Title
NCT06439615	BLISS	P2	not yet recruiting	Baricitinib for the Lung Injury Following Spontaneous SAH

Frontal Fibrosing Alopecia (1)

NCT	Acronym	Phase	Status	Title
NCT06240351	FFA	P4	active not recruiting	A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

Lichen Planus, Oral (1)

NCT	Acronym	Phase	Status	Title
NCT06158113	—	P2	active not recruiting	Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study

Pulmonary Injury After Intracerebral Hemorrhage (1)

NCT	Acronym	Phase	Status	Title
NCT06548802	BRIGHT	P1/P2	recruiting	Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury

Diffuse Cutaneous Systemic Sclerosis (1)

NCT	Acronym	Phase	Status	Title
NCT06936215	BardSSc	P3	recruiting	Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate

HIV (1)

NCT	Acronym	Phase	Status	Title
NCT05849038	—	P2	recruiting	Inflammation and Depression in People With HIV

Acute Lymphoblastic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT06475820	—	P2/P3	active not recruiting	Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Traumatic Brain Injury (1)

NCT	Acronym	Phase	Status	Title
NCT06065046	—	P2	recruiting	Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions

Spondyloarthritis, Axial (1)

NCT	Acronym	Phase	Status	Title
NCT06114407	—	P2	unknown	Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib

Pyoderma Gangrenosum (1)

NCT	Acronym	Phase	Status	Title
NCT04901325	PG	P2	completed	Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)

Hospital-acquired Pneumonia (1)

NCT	Acronym	Phase	Status	Title
NCT05914584	TREAT-HAP	P2/P3	unknown	"Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.

Human Immunodeficiency Virus (1)

NCT	Acronym	Phase	Status	Title
NCT05452564	—	P2	recruiting	Baricitinib for Reduction of HIV - CNS

Mastitis Chronic (1)

NCT	Acronym	Phase	Status	Title
NCT05852171	B-IGM	P2	unknown	Baricitinib in Idiopathic Granulomatous Mastitis

Chronic Kidney Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT05237388	JUSTICE	P2	completed	Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease

NMO Spectrum Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT05792462	—	P1/P2	recruiting	Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders

Takayasu Arteritis (1)

NCT	Acronym	Phase	Status	Title
NCT06662721	—	P2	completed	Baricitinib for Refractory Takayasu Arteritis

Areata Alopecia (1)

NCT	Acronym	Phase	Status	Title
NCT05723198	BRAVE-AA-PEDS	P3	recruiting	A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

IgG4-related Disease With Eosinophilia (1)

NCT	Acronym	Phase	Status	Title
NCT05781516	—	N/A	unknown	Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD

Amyotrophic Lateral Sclerosis (1)

NCT	Acronym	Phase	Status	Title
NCT05189106	NADALS	P1/P2	completed	Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial

Juvenile Dermatomyositis (1)

NCT	Acronym	Phase	Status	Title
NCT05524311	MYOCIT	P2	completed	Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)

ITP (1)

NCT	Acronym	Phase	Status	Title
NCT05446831	BAITP	P2	unknown	Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia

Lupus or SLE (1)

NCT	Acronym	Phase	Status	Title
NCT05686746	—	P2/P3	unknown	Use of Baricitenib to Maintain of Remission

Systemic Sclerosis (1)

NCT	Acronym	Phase	Status	Title
NCT05300932	—	P4	active not recruiting	A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis

Mucous Membrane Pemphigoid (1)

NCT	Acronym	Phase	Status	Title
NCT05263505	—	P2	terminated	Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

Cutaneous Lichen Planus (1)

NCT	Acronym	Phase	Status	Title
NCT05188521	LY3009104	P2	completed	Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

Idiopathic Inflammatory Myopathies (1)

NCT	Acronym	Phase	Status	Title
NCT04208464	MYOJAK	P2	completed	JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM

Vitiligo (1)

NCT	Acronym	Phase	Status	Title
NCT04822584	BARVIT	P2	completed	Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

Polymyalgia Rheumatic (PMR) (1)

NCT	Acronym	Phase	Status	Title
NCT04027101	BACHELOR	P2	completed	BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica

Type 1 Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT04774224	BANDIT	P2	completed	Baricitinib in New-onset Type 1 Diabetes

Nakajo-Nishimura Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT04517253	LY3009104	P2/P3	terminated	A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

COVID-19 Severe Respiratory Failure (1)

NCT	Acronym	Phase	Status	Title
NCT05279391	—	N/A	unknown	Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19

Allergic Contact Dermatitis (1)

NCT	Acronym	Phase	Status	Title
NCT03945760	—	Early P1	completed	Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

Covid-19 (1)

NCT	Acronym	Phase	Status	Title
NCT04393051	BARICIVID-19	P2	unknown	Baricitinib Compared to Standard Therapy in Patients With COVID-19

Pharmacological Action (1)

NCT	Acronym	Phase	Status	Title
NCT04320277	BARI-COVID	P2/P3	unknown	Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.

Corona Virus Infection (1)

NCT	Acronym	Phase	Status	Title
NCT04399798	BREATH	P2	unknown	Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial

COVID19 (1)

NCT	Acronym	Phase	Status	Title
NCT04390464	TACTIC-R	P4	unknown	mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)

Symptomatic COVID-19 Infection Laboratory-Confirmed (1)

NCT	Acronym	Phase	Status	Title
NCT04373044	—	P2	terminated	Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19

Graft-versus-host-disease (1)

NCT	Acronym	Phase	Status	Title
NCT04131738	—	P1	completed	Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation

SARS-CoV-2 Infection (1)

NCT	Acronym	Phase	Status	Title
NCT04890626	—	P3	completed	Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19

Pneumonia (1)

NCT	Acronym	Phase	Status	Title
NCT04381936	RECOVERY	P3	recruiting	Randomised Evaluation of COVID-19 Therapy

COVID (1)

NCT	Acronym	Phase	Status	Title
NCT04358614	—	P2/P3	completed	Baricitinib Therapy in COVID-19

Systemic Juvenile Idiopathic Arthritis (1)

NCT	Acronym	Phase	Status	Title
NCT04088396	LY3009104	P3	recruiting	A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Uveitis (1)

NCT	Acronym	Phase	Status	Title
NCT04088409	LY3009104	P3	active not recruiting	A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Aicardi Goutieres Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT03921554	—	P2	completed	JAK Inhibitor Treatment in AGS

Primary Biliary Cholangitis (1)

NCT	Acronym	Phase	Status	Title
NCT03742973	LY3009104	P2	terminated	A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

Arteritis, Giant Cell (1)

NCT	Acronym	Phase	Status	Title
NCT03026504	—	P2	completed	Baricitinib in Relapsing Giant Cell Arteritis

Chronic Graft vs Host Disease (1)

NCT	Acronym	Phase	Status	Title
NCT02759731	—	P1/P2	completed	Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Community-acquired Pneumonia, Influenza, COVID-19 (1)

NCT	Acronym	Phase	Status	Title
NCT02735707	REMAP-CAP	P3	recruiting	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Healthy Participants (1)

NCT	Acronym	Phase	Status	Title
NCT02263911	—	P1	completed	A Study of Baricitinib in Healthy Japanese Participants

Liver Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT01870388	—	P1	completed	A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease

Psoriasis (1)

NCT	Acronym	Phase	Status	Title
NCT01490632	—	P2	completed	A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

Arthritis, Rheumatoid (1)

NCT	Acronym	Phase	Status	Title
NCT01469013	LY3009104	P2	completed	Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy

Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE) (1)

NCT	Acronym	Phase	Status	Title
NCT01724580	—	N/A	approved for marketing	Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

Baricitinib pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
JAK-TAP	NCT06687551	P4	not yet recruiting	Rhumatoid Arthisis	308	—
FFA	NCT06240351	P4	active not recruiting	Frontal Fibrosing Alopecia	15	—
BAR-RA	NCT07357649	P4	not yet recruiting	Rheumatoid Arthritis	100	—
RA-BRIDGE	NCT03915964	P4	completed	Rheumatoid Arthritis	2,663	—
RA-BRANCH	NCT04086745	P4	completed	Rheumatoid Arthritis	1,317	—
COVER	NCT05080218	P4	completed	Rheumatoid Arthritis	841	—
BARICENTRE	NCT05238896	P4	terminated	Rheumatoid Arthritis	5	—
TACTIC-R	NCT04390464	P4	unknown	COVID19	1,167	PMID 32641154
RECOVERY	NCT04381936	P3	recruiting	Pneumonia	70,000	PMID 38296965
BRAVE-AA-PEDS	NCT05723198	P3	recruiting	Areata Alopecia	595	—
DEN-HOST	NCT07543458	P3	not yet recruiting	Dengue	8,800	—
BARICADE-DELAY	NCT07222137	P3	recruiting	Diabetes Mellitus, Type 1	150	—
JUVE-X	NCT03773965	P3	recruiting	Juvenile Idiopathic Arthritis	190	—
JAKUVEITE	NCT05651880	P3	not yet recruiting	Active Non-anterior Non-infectious Uveitis	33	—
REVERSE-LC	NCT05858515	P3	withdrawn	Post-Acute COVID-19 Syndrome	0	—
JADORE-BARI	NCT07279688	P3	recruiting	Polymyalgia Rheumatica (PMR)	140	—
LY3009104	NCT07222332	P3	recruiting	Diabetes Mellitus, Type 1	300	—
LY3009104	NCT04088409	P3	active not recruiting	Uveitis	30	PMID 34627340
REMAP-CAP	NCT02735707	P3	recruiting	Community-acquired Pneumonia, Influenza, COVID-19	20,000	PMID 37039790
BIRD	NCT04972760	P3	recruiting	Dermatomyositis	62	—
REVERSE-LC	NCT06631287	P3	recruiting	Long COVID	550	—
CRI-RA	NCT04870203	P3	active not recruiting	Rheumatoid Arthritis	160	—
LY3009104	NCT04088396	P3	recruiting	Systemic Juvenile Idiopathic Arthritis	58	—
BREEZE-AD-PEDS	NCT03952559	P3	active not recruiting	Atopic Dermatitis	516	PMID 39522957
BardSSc	NCT06936215	P3	recruiting	Diffuse Cutaneous Systemic Sclerosis	24	—
BRAVE-AA2	NCT03899259	P3	completed	Alopecia Areata	606	PMID 36855020
COV-BARRIER	NCT05074420	P3	terminated	Covid19	6	—
BREEZE-AD3	NCT03334435	P3	completed	Atopic Dermatitis	1,645	PMID 36912484
BREEZE-AD4	NCT03428100	P3	completed	Atopic Dermatitis	463	—
AMMURAVID	NCT04832880	P3	unknown	Covid19	4,000	—
BREEZE-AD6	NCT03559270	P3	terminated	Atopic Dermatitis	374	PMID 36749121
SLE-BRAVE-X	NCT03843125	P3	terminated	Systemic Lupus Erythematosus	1,147	—
SLE-BRAVE I	NCT03616912	P3	terminated	Systemic Lupus Erythematosus	830	PMID 40305472
JUVE-BASIS	NCT03773978	P3	completed	Juvenile Idiopathic Arthritis	220	PMID 37423231
BRAVE II	NCT03616964	P3	completed	Systemic Lupus Erythematosus	778	PMID 36848919
BAREBONE	NCT03701789	P3	unknown	Rheumatoid Arthritis	15	PMID 37229650
BREEZE-AD5	NCT03435081	P3	completed	Atopic Dermatitis	440	PMID 35442530
ACTT-4	NCT04640168	P3	completed	COVID-19	1,010	PMID 35617986
COV-BARRIER	NCT04421027	P3	completed	COVID-19	1,525	PMID 34480861
RA-BEYOND	NCT01885078	P3	completed	Rheumatoid Arthritis	2,877	PMID 30999933
ACTT-2	NCT04401579	P3	completed	COVID-19	1,033	PMID 38408357
BREEZE-AD7	NCT03733301	P3	completed	Atopic Dermatitis	329	PMID 34275122
BREEZE-AD1	NCT03334396	P3	completed	Atopic Dermatitis	660	PMID 33826132
BREEZE-AD2	NCT03334422	P3	completed	Atopic Dermatitis	615	PMID 34688290
LY3009104	NCT02265705	P3	completed	Rheumatoid Arthritis	290	PMID 33959198
RA-BEAM	NCT01710358	P3	completed	Rheumatoid Arthritis	1,307	PMID 29680881
RA-BEGIN	NCT01711359	P3	completed	Rheumatoid Arthritis	588	PMID 34526397
RA-BUILD	NCT01721057	P3	completed	Rheumatoid Arthritis	684	PMID 33046136
RA-BEACON	NCT01721044	P3	completed	Rheumatoid Arthritis	527	PMID 34028703
PALETTE	NCT06381661	P2	not yet recruiting	Sepsis	2,000	—
BOOSTERS	NCT07268534	P2	not yet recruiting	Folliculitis Decalvans (FD)	120	—
JAKIH	NCT06490757	P2	recruiting	Inflammatory Hepatocellular Adenoma	25	PMID 16496320
BLISS	NCT06439615	P2	not yet recruiting	Spontaneous Subarachnoid Hemorrhage	100	PMID 37445562
BAPTIST	NCT06768294	P2	not yet recruiting	Calcium Pyrophosphate Deposition Disease	32	PMID 21257614
MQ7422	NCT06797310	P2	not yet recruiting	Alopecia Areata	30	—
JUSTICE	NCT05237388	P2	completed	Chronic Kidney Diseases	8	PMID 41236849
MYOCIT	NCT05524311	P2	completed	Juvenile Dermatomyositis	16	PMID 7986222
B-IGM	NCT05852171	P2	unknown	Mastitis Chronic	20	—
PG	NCT04901325	P2	completed	Pyoderma Gangrenosum	5	PMID 23953278
WP3	NCT05897372	P2	terminated	Diabetic Kidney Disease	1	—
BANDIT	NCT04774224	P2	completed	Type 1 Diabetes	91	PMID 38055252
COVID-19	NCT04321993	P2	unknown	COVID-19	363	—
BAITP	NCT05446831	P2	unknown	ITP	35	PMID 38980207
MYOJAK	NCT04208464	P2	completed	Idiopathic Inflammatory Myopathies	15	—
BACHELOR	NCT04027101	P2	completed	Polymyalgia Rheumatic (PMR)	34	PMID 39818228
LY3009104	NCT05188521	P2	completed	Cutaneous Lichen Planus	12	PMID 39951132
BARVIT	NCT04822584	P2	completed	Vitiligo	49	PMID 39841460
Covid19COVINIB	NCT04346147	P2	unknown	COVID-19 Pneumonia	168	—
BREATH	NCT04399798	P2	unknown	Corona Virus Infection	13	—
BARICIVID-19	NCT04393051	P2	unknown	Covid-19	126	PMID 32032529
LY3009104	NCT03742973	P2	terminated	Primary Biliary Cholangitis	2	—
LY3009104	NCT02708095	P2	completed	Systemic Lupus Erythematosus	314	PMID 30043749
LY3009104	NCT02576938	P2	completed	Atopic Dermatitis	124	—
LY3009104	NCT01469013	P2	completed	Arthritis, Rheumatoid	145	PMID 28440680

Terminated and withdrawn Baricitinib trials (15)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT05858515withdrawnREVERSE-Long COVID-19 With Baricitinib Study
NCT04517253terminatedA Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
NCT05074420terminatedA Study of Baricitinib (LY3009104) in Children With COVID-19
NCT05897372terminatedFeasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study
NCT05263505terminatedBaricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
NCT05238896terminatedBARIcitinib Cognitive Emotional and Neural signaTuRE
NCT05361109withdrawnBaricitinib for Cutaneous Dermatomyositis
NCT04891133terminatedEU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial
NCT03559270terminatedA Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis
NCT03843125terminatedA Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
NCT03616912terminatedA Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus
NCT04970719withdrawnBaricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus
NCT04340232withdrawnSafety and Efficacy of Baricitinib for COVID-19
NCT04373044terminatedBaricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
NCT03742973terminatedA Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

All Baricitinib trials (156)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT04381936	RECOVERY	Randomised Evaluation of COVID-19 Therapy	P3	recruiting	70,000	University of Oxford	Mar 2020
NCT05723198	BRAVE-AA-PEDS	A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata	P3	recruiting	595	Eli Lilly and Company	Feb 2023
NCT05003310		ConsideRAte Study - Splenic Stimulation for RA	N/A	recruiting	28	Galvani Bioelectronics	Oct 2021
NCT07543458	DEN-HOST	Therapeutics for Moderate and Severe Dengue	P3	not yet recruiting	8,800	Oxford University Clinical Research Unit, Vietnam	Oct 2026
NCT07222137	BARICADE-DELAY	A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults	P3	recruiting	150	Eli Lilly and Company	Jan 2026
NCT03773965	JUVE-X	A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis	P3	recruiting	190	Eli Lilly and Company	Apr 2019
NCT07448363		Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica	—	not yet recruiting	50	Caja Costarricense de Seguro Social	May 2026
NCT06381661	PALETTE	Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial	P2	not yet recruiting	2,000	Assistance Publique - Hôpitaux de Paris	May 2026
NCT06923072		Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement	P2	recruiting	12	National Heart, Lung, and Blood Institute (NHLBI)	Feb 2026
NCT07081763		Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption	P2	not yet recruiting	191	ANRS, Emerging Infectious Diseases	May 2026
NCT07262983		Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis	P1	recruiting	20	National Institute of Allergy and Infectious Diseases (NIAID)	Jun 2026
NCT07268534	BOOSTERS	Biologics in Folliculitis Decalvans : an Adaptative Trial Research	P2	not yet recruiting	120	Assistance Publique - Hôpitaux de Paris	Apr 2026
NCT07003997		JAK Signaling in Depression	P2	recruiting	100	Emory University	Sep 2025
NCT05651880	JAKUVEITE	Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis	P3	not yet recruiting	33	University Hospital, Rouen	Jul 2026
NCT03358693	MSID	Molecular Signatures in Inflammatory Skin Disease	—	recruiting	300	Prof. Dr. Stephan Weidinger	Jan 2017
NCT05858515	REVERSE-LC	REVERSE-Long COVID-19 With Baricitinib Study	P3	withdrawn	0	Vanderbilt University Medical Center	Oct 2024
NCT07535645	BAPT	Baricitinib for Post-HSCT Persistent Thrombocytopenia	P1/P2	not yet recruiting	28	Peking University People's Hospital	Apr 2026
NCT07279688	JADORE-BARI	Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica	P3	recruiting	140	University Hospital, Brest	Dec 2025
NCT06687551	JAK-TAP	JAK Inhibitor Dose TAPering Strategy Study	P4	not yet recruiting	308	University Hospital, Toulouse	Jan 2025
NCT03414502		Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response	P3	recruiting	400	University of Nebraska	Dec 2007
NCT07554222		Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration	P1	recruiting	160	Innovent Biologics (Suzhou) Co. Ltd.	Apr 2026
NCT06868381		A Trial of Baricitinib in Patients With Cardiac Sarcoidosis	P2	not yet recruiting	10	Stanford University	Apr 2026
NCT06490757	JAKIH	A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas	P2	recruiting	25	Assistance Publique - Hôpitaux de Paris	Oct 2024
NCT07222332	LY3009104	A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)	P3	recruiting	300	Eli Lilly and Company	Feb 2026
NCT04088409	LY3009104	A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis	P3	active not recruiting	30	Eli Lilly and Company	Oct 2019
NCT06849908		Baricitinib in the Treatment of Intestinal Behçet's Syndrome	P2	recruiting	56	Peking Union Medical College Hospital	Nov 2024
NCT02735707	REMAP-CAP	Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia	P3	recruiting	20,000	UMC Utrecht	Apr 2016
NCT04972760	BIRD	Baricitinib in Patients With Relapsing or naïve Dermatomyositis	P3	recruiting	62	Assistance Publique - Hôpitaux de Paris	Aug 2022
NCT07209267		Baricitinib Curative Repression of HIV-1	P2	not yet recruiting	20	Emory University	Jul 2026
NCT07449910		Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial	P2/P3	not yet recruiting	750	The First Affiliated Hospital of University of Science and Technology of China	Mar 2026
NCT05452564		Baricitinib for Reduction of HIV - CNS	P2	recruiting	95	William Tyor	May 2023
NCT05849038		Inflammation and Depression in People With HIV	P2	recruiting	60	Emory University	Dec 2023
NCT06240351	FFA	A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)	P4	active not recruiting	15	University of Alabama at Birmingham	Apr 2024
NCT06631287	REVERSE-LC	Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID	P3	recruiting	550	Wes Ely	Oct 2024
NCT06439615	BLISS	Baricitinib for the Lung Injury Following Spontaneous SAH	P2	not yet recruiting	100	Tang-Du Hospital	Aug 2024
NCT06475820		Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis	P2/P3	active not recruiting	150	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Dec 2023
NCT04870203	CRI-RA	Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis	P3	active not recruiting	160	University Hospital, Bordeaux	Jul 2021
NCT06768294	BAPTIST	Baricitinib in CPPD - the BAPTIST Study	P2	not yet recruiting	32	I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio	Jan 2025
NCT07357649	BAR-RA	Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis	P4	not yet recruiting	100	Tanta University	Jan 2026
NCT06797310	MQ7422	Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study	P2	not yet recruiting	30	National Taiwan University Hospital	Jan 2025
NCT06573593		Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study	—	recruiting	150	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jul 2024
NCT06065046		Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions	P2	recruiting	100	Tang-Du Hospital	Nov 2023
NCT05300932		A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis	P4	active not recruiting	60	Tongji Hospital	Mar 2022
NCT06158113		Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study	P2	active not recruiting	10	University of North Carolina, Chapel Hill	Mar 2024
NCT04088396	LY3009104	A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)	P3	recruiting	58	Eli Lilly and Company	Feb 2020
NCT06548802	BRIGHT	Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury	P1/P2	recruiting	100	Tianjin Medical University General Hospital	Feb 2024
NCT05955066		Effect of JAK Inhibitor on Erosion Healing in RA	P4	recruiting	60	Chinese University of Hong Kong	Dec 2023
NCT03952559	BREEZE-AD-PEDS	A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis	P3	active not recruiting	516	Eli Lilly and Company	May 2019
NCT05237388	JUSTICE	Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease	P2	completed	8	Duke University	Apr 2023
NCT05524311	MYOCIT	Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)	P2	completed	16	Assistance Publique - Hôpitaux de Paris	Nov 2022
NCT05914584	TREAT-HAP	"Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.	P2/P3	unknown	450	Nantes University Hospital	Jul 2023
NCT05852171	B-IGM	Baricitinib in Idiopathic Granulomatous Mastitis	P2	unknown	20	First Affiliated Hospital of Zhejiang University	May 2023
NCT05792462		Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders	P1/P2	recruiting	12	Tianjin Medical University General Hospital	Apr 2023
NCT03755466		Examination of Efficacy and Safety of Baricitinib in RA Patients	P2	unknown	90	Shinshu University	Nov 2018
NCT05969730		Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis	N/A	completed	40	Mazandaran University of Medical Sciences	Aug 2023
NCT06768840		Vitiligo, New Treatment and Serum s100B	P2/P3	recruiting	50	South Valley University	Oct 2024
NCT05932524		Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia	P2	unknown	132	Peking University People's Hospital	Jul 2023
NCT05781516		Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD	N/A	unknown	74	Wen Zhang	Jan 2023
NCT05189106	NADALS	Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial	P1/P2	completed	17	Massachusetts General Hospital	Dec 2022
NCT06936215	BardSSc	Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate	P3	recruiting	24	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Jan 2024
NCT05852847		Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia	P2	unknown	216	Peking University People's Hospital	May 2023
NCT03915964	RA-BRIDGE	A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis	P4	completed	2,663	Eli Lilly and Company	Apr 2019
NCT04086745	RA-BRANCH	A Study of Baricitinib in Participants With Rheumatoid Arthritis	P4	completed	1,317	Eli Lilly and Company	Feb 2020
NCT04901325	PG	Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)	P2	completed	5	Oregon Health and Science University	Oct 2023
NCT03440892	SurviTreat	Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients	—	unknown	2,500	Vastra Gotaland Region	Nov 2017
NCT03570749	BRAVE-AA1	A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata	P2/P3	completed	784	Eli Lilly and Company	Sep 2018
NCT06114407		Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib	P2	unknown	184	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Oct 2023
NCT05950542		Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo	—	unknown	30	Assiut University	Sep 2023
NCT04517253	LY3009104	A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS	P2/P3	terminated	10	Eli Lilly and Company	Oct 2020
NCT05016297		Efficacy and Safety of Baricitinib in Sjogren's Syndrome	P2	completed	87	Peking Union Medical College Hospital	Jul 2022
NCT03899259	BRAVE-AA2	A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata	P3	completed	606	Eli Lilly and Company	Jul 2019
NCT05074420	COV-BARRIER	A Study of Baricitinib (LY3009104) in Children With COVID-19	P3	terminated	6	Eli Lilly and Company	Dec 2021
NCT06545110		Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib	P1	active not recruiting	120	South Valley University	Sep 2023
NCT05897372	WP3	Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study	P2	terminated	1	Iain Bressendorff	Aug 2023
NCT04449224		Comparative Effectiveness of Targeted Therapy in RA Patients	—	unknown	506	Hanyang University	Apr 2020
NCT06662721		Baricitinib for Refractory Takayasu Arteritis	P2	completed	10	Liu Tian	Apr 2023
NCT02759731		Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation	P1/P2	completed	24	National Cancer Institute (NCI)	Nov 2016
NCT05080218	COVER	COVID-19 VaccinE Response in Rheumatology Patients	P4	completed	841	Jeffrey Curtis	Nov 2021
NCT04774224	BANDIT	Baricitinib in New-onset Type 1 Diabetes	P2	completed	91	St Vincent's Institute of Medical Research	Oct 2020
NCT04321993	COVID-19	Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients	P2	unknown	363	Lisa Barrett	Apr 2020
NCT05827497		Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical Trial	P4	unknown	132	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Apr 2023
NCT03921554		JAK Inhibitor Treatment in AGS	P2	completed	54	Adeline Vanderver, MD	Jun 2019
NCT05279391		Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19	N/A	unknown	150	Democritus University of Thrace	Oct 2020
NCT05446831	BAITP	Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia	P2	unknown	35	Peking University People's Hospital	Jul 2022
NCT03945760		Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects	Early P1	completed	23	Wright State Physicians	Sep 2020
NCT05660655		Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis	P4	completed	94	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Oct 2022
NCT04208464	MYOJAK	JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM	P2	completed	15	University of Manchester	Oct 2021
NCT05638932		Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments	—	completed	1,442	Aetion, Inc.	Jun 2020
NCT05263505		Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid	P2	terminated	2	Washington University School of Medicine	Feb 2022
NCT04027101	BACHELOR	BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica	P2	completed	34	University Hospital, Brest	Dec 2020
NCT05686746		Use of Baricitenib to Maintain of Remission	P2/P3	unknown	80	Assiut University	Jun 2022
NCT04890626		Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19	P3	completed	356	Instituto de Investigación Hospital Universitario La Paz	Apr 2020
NCT03334435	BREEZE-AD3	A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis	P3	completed	1,645	Eli Lilly and Company	Mar 2018
NCT05188521	LY3009104	Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus	P2	completed	12	Aaron R. Mangold	Jan 2022
NCT04822584	BARVIT	Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo	P2	completed	49	University Hospital, Bordeaux	Jul 2021
NCT03428100	BREEZE-AD4	A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable	P3	completed	463	Eli Lilly and Company	May 2018
NCT05238896	BARICENTRE	BARIcitinib Cognitive Emotional and Neural signaTuRE	P4	terminated	5	Assistance Publique - Hôpitaux de Paris	Jun 2022
NCT05361109		Baricitinib for Cutaneous Dermatomyositis	P2	withdrawn	0	University of Washington	Jun 2022
NCT04891133	Bari-SolidAct	EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial	P2/P3	terminated	290	Oslo University Hospital	Jun 2021
NCT04832880	AMMURAVID	Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)	P3	unknown	4,000	ASST Fatebenefratelli Sacco	Apr 2021
NCT05056558		Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19	P3	unknown	480	Incepta Pharmaceuticals Ltd	Oct 2021
NCT04131738		Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation	P1	completed	26	Washington University School of Medicine	Apr 2020
NCT03559270	BREEZE-AD6	A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis	P3	terminated	374	Eli Lilly and Company	Jun 2018
NCT05082714		Tocilizumab Versus Baricitinib in Patients With Severe COVID-19	N/A	completed	251	University Hospital of Patras	Oct 2021
NCT04390464	TACTIC-R	mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)	P4	unknown	1,167	Cambridge University Hospitals NHS Foundation Trust	May 2020
NCT03843125	SLE-BRAVE-X	A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)	P3	terminated	1,147	Eli Lilly and Company	Sep 2019
NCT03616912	SLE-BRAVE I	A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus	P3	terminated	830	Eli Lilly and Company	Aug 2018
NCT03773978	JUVE-BASIS	A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis	P3	completed	220	Eli Lilly and Company	Dec 2018
NCT04970719		Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus	P3	withdrawn	0	Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders	Jul 2021
NCT04340232		Safety and Efficacy of Baricitinib for COVID-19	P2/P3	withdrawn	0	University of Colorado, Denver	Mar 2021
NCT03616964	BRAVE II	A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)	P3	completed	778	Eli Lilly and Company	Aug 2018
NCT03701789	BAREBONE	Effect of Baricitinib Treatment on Peripheral Bone in RA	P3	unknown	15	University of Erlangen-Nürnberg Medical School	Sep 2018
NCT04346147	Covid19COVINIB	Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19	P2	unknown	168	Hospital Universitario de Fuenlabrada	May 2020
NCT03435081	BREEZE-AD5	A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis	P3	completed	440	Eli Lilly and Company	Feb 2018
NCT05302947		COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU	—	completed	154	Pirogov Russian National Research Medical University	Feb 2020
NCT04640168	ACTT-4	Adaptive COVID-19 Treatment Trial 4 (ACTT-4)	P3	completed	1,010	National Institute of Allergy and Infectious Diseases (NIAID)	Dec 2020
NCT04421027	COV-BARRIER	A Study of Baricitinib (LY3009104) in Participants With COVID-19	P3	completed	1,525	Eli Lilly and Company	Jun 2020
NCT04373044		Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19	P2	terminated	6	University of Southern California	May 2020
NCT04362943	COVID-AGE	Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults	—	completed	576	Complejo Hospitalario Universitario de Albacete	Apr 2020
NCT03026504		Baricitinib in Relapsing Giant Cell Arteritis	P2	completed	15	Matthew J Koster	Mar 2017
NCT04916756		A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients	P1/P2	completed	11	Peking Union Medical College Hospital	Jan 2020
NCT04693026		Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients	P3	unknown	150	M Abdur Rahim Medical College and Hospital	Sep 2020
NCT04399798	BREATH	Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial	P2	unknown	13	Fondazione IRCCS Policlinico San Matteo di Pavia	May 2020
NCT01885078	RA-BEYOND	An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis	P3	completed	2,877	Eli Lilly and Company	Jun 2013
NCT04401579	ACTT-2	Adaptive COVID-19 Treatment Trial 2 (ACTT-2)	P3	completed	1,033	National Institute of Allergy and Infectious Diseases (NIAID)	May 2020
NCT04393051	BARICIVID-19	Baricitinib Compared to Standard Therapy in Patients With COVID-19	P2	unknown	126	Azienda Ospedaliero, Universitaria Pisana	May 2020
NCT04320277	BARI-COVID	Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.	P2/P3	unknown	200	Hospital of Prato	May 2020
NCT04358614		Baricitinib Therapy in COVID-19	P2/P3	completed	12	Fabrizio Cantini	Mar 2020
NCT03742973	LY3009104	A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA	P2	terminated	2	Eli Lilly and Company	Mar 2019
NCT03733301	BREEZE-AD7	A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis	P3	completed	329	Eli Lilly and Company	Nov 2018
NCT03334396	BREEZE-AD1	A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis	P3	completed	660	Eli Lilly and Company	Nov 2017
NCT03334422	BREEZE-AD2	Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis	P3	completed	615	Eli Lilly and Company	Nov 2017
NCT02708095	LY3009104	A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)	P2	completed	314	Eli Lilly and Company	Mar 2016
NCT03212638		A Study of Baricitinib in Healthy Participants	P1	completed	42	Eli Lilly and Company	Jun 2017
NCT02265705	LY3009104	A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)	P3	completed	290	Eli Lilly and Company	Oct 2014
NCT02576938	LY3009104	A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis	P2	completed	124	Eli Lilly and Company	Feb 2016
NCT02758613	LY3009104	A Study of Baricitinib (LY3009104) in Healthy Chinese Participants	P1	completed	33	Eli Lilly and Company	May 2016
NCT01710358	RA-BEAM	A Study in Moderate to Severe Rheumatoid Arthritis	P3	completed	1,307	Eli Lilly and Company	Oct 2012
NCT01711359	RA-BEGIN	A Study in Participants With Moderate to Severe Rheumatoid Arthritis	P3	completed	588	Eli Lilly and Company	Nov 2012
NCT02340104	LY3009104	A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants	P1	completed	8	Eli Lilly and Company	Jan 2015
NCT02263911		A Study of Baricitinib in Healthy Japanese Participants	P1	completed	16	Eli Lilly and Company	Nov 2014
NCT01721057	RA-BUILD	A Study in Moderate to Severe Rheumatoid Arthritis Participants	P3	completed	684	Eli Lilly and Company	Dec 2012
NCT01683409		A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease	P2	completed	130	Eli Lilly and Company	Aug 2012
NCT01721044	RA-BEACON	A Moderate to Severe Rheumatoid Arthritis Study	P3	completed	527	Eli Lilly and Company	Jan 2013
NCT01490632		A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis	P2	completed	271	Eli Lilly and Company	Dec 2011
NCT01960140		A Study of Baricitinib and Simvastatin in Healthy Participants	P1	completed	40	Eli Lilly and Company	Oct 2013
NCT01968057		A Study of Baricitinib and Ciclosporin in Healthy Participants	P1	completed	18	Eli Lilly and Company	Oct 2013
NCT01469013	LY3009104	Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy	P2	completed	145	Eli Lilly and Company	Nov 2011
NCT01925144		A Study of Baricitinib and Omeprazole in Healthy Participants	P1	completed	30	Eli Lilly and Company	Oct 2013
NCT01937026		A Study of Baricitinib and Probenecid in Healthy Participants	P1	completed	18	Eli Lilly and Company	Sep 2013
NCT01924299		A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants	P1	completed	36	Eli Lilly and Company	Aug 2013
NCT01910311		A Study of Baricitinib and Rifampicin in Healthy Participants	P1	completed	18	Eli Lilly and Company	Aug 2013
NCT01896726		A Study of Baricitinib and Birth Control Pills in Healthy Females	P1	completed	20	Eli Lilly and Company	Jul 2013
NCT01859078	DDI	A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants	P1	completed	28	Eli Lilly and Company	May 2013
NCT01870388		A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease	P1	completed	16	Eli Lilly and Company	Jun 2013
NCT01724580		Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes	—	approved for marketing	0	Eli Lilly and Company	—

Baricitinib clinical trials: frequently asked questions

How many Baricitinib clinical trials are there?: 156 Baricitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 28 are actively recruiting participants. 65 are marked completed.
Are Baricitinib clinical trials recruiting in 2026?: Yes — 28 Baricitinib trials are actively recruiting in 2026, with 73 U.S. sites across 29 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Baricitinib being studied for?: Baricitinib is being studied for Rheumatoid Arthritis, Atopic Dermatitis, COVID-19, Healthy Volunteers, Alopecia Areata and 149 more. The trials are grouped by indication on this page.
What phase is Baricitinib in?: Baricitinib clinical trials span 12 Phase 4, 46 Phase 3, 48 Phase 2, 17 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Baricitinib clinical trials?: The lead sponsor across the most Baricitinib trials is Eli Lilly and Company, with 81 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Baricitinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.

Related pages on Hipa.ai:

Baricitinib overview Baricitinib evidence & publications